D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters

 

Status: Ongoing

Details

The aim of this study is to learn more about the drug called benralizumab (Fasenra®) and to better understand how it works in the treatment of severe eosinophilic asthma.

Sponsor: AstraZeneca

NCT05552508 - IRB#2022-107